The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis

Arthritis Care and Research

Volumn 49, Issue 3, 2003, Pages 283-292

  Maetzel, Andreas ^a   Krahn, Murray ^a   Naglie, Gary ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

Cost effectiveness; Cyclooxygenase 2 inhibitors; Nonsteroidal antiinflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTACID AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

AGING; ARTICLE; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; DUODENUM ULCER; DYSPEPSIA; EVALUATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIGH RISK POPULATION; HOSPITAL COST; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STOMACH ULCER; THEORETICAL MODEL;

EID: 0038312958     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11121     Document Type: Article

References (44)

1. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-40.
2. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs [review]. N Engl J Med 1999;340:1888-99.
4. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
5. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995:123:241-9.
6. Hernandez-Diaz S, Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093-9.
7. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci U S A 1993;90:11693-7.
8. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
9. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
10. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis: Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160:1781-7.
11. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
12. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
13. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
14. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd ed. Ottawa: CCOHTA; 1997.
15. Goldkind L. Medical officer's advisory committee GI briefing document division of anti-inflammatory, analgesic and ophthalmologic drug products: HFD-550. NDA 21-042; 2001. p. 1-56.
16. Witter J. Medical officer review: sNDA 20 998, 1-100. Rockville (MD): U.S. Food and Drug Administration; 2001.
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
18. Jones RH, Tait CL. Gastrointestinal side-effects of NSAIDs in the community. Br J Clin Pract 1995;49:67-70.
19. Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000;43:917-24.
20. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: omeprazole versus misoprostol for NSAID-induced ulcer management (OMNIUM) study group. N Engl J Med 1998;338:727-34.
21. Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997: arthritis, rheumatism, and aging medical information system. J Rheumatol Suppl 1998;51:8-16.
22. Bakowsky VS, Hanly JG. Complications of nonsteroidal antiinflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center. J Rheumatol 1999;26:1557-63.
23. Wilcox CM, Clark WS. Association of nonsteroidal antiinflammatory drugs with outcome in upper and lower gastrointestinal bleeding. Dig Dis Sci 1997;42:985-9.
24. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut 1991;32:730-4.
25. Laszlo A, Kelly JP, Kaufman DE, Sheehan JE, Retsagi G, Wiholm BE, et al. Clinical aspects of upper gastrointestinal bleeding associated with the use of nonsteroidal antiinflammatory drugs. Am J Gastroenterol 1998;93:721-5.
26. Klein WA, Krevsky B, Klepper L, Ljubich P, Niewiarowski TJ, Rothstein KD, et al. Nonsteroidal antiinflammatory drugs and upper gastrointestinal hemorrhage in an urban hospital. Dig Dis Sci 1993;38:2049-55.
27. Branicki FJ, Coleman SY, Fok PJ, Pritchett CJ, Fan ST, Lai EC, et al. Bleeding peptic ulcer: a prospective evaluation of risk factors for rebleeding and mortality. World J Surg 1990;14:262-9.
28. Duhamel C, Czernichow P, Dechelotte P, Ducrotte P, Lerebours E, Colin, et al. [Upper gastrointestinal hemorrhage caused by anti-inflammatory agents]. [French]. Gastroenterol Clin Biol 1989;13:239-44.
29. Godil A, DeGuzman L, Schilling RC III, Khan SA, Chen YK. Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence of bleeding in patients presenting with bleeding ulcer. Gastrointest Endosc 2000;51:146-51.
30. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1998;41:16-25.
31. Loperfido S, Monica F, Maifreni L, Paccagnella A, Fama R, Dal Pos R, et al. Bleeding peptic ulcer occurring in hospitalized patients: analysis of predictive and risk factors and comparison with out-of-hospital onset of hemorrhage. Dig Dis Sci 1994;39:698-705.
32. Katschinski B, Logan R, Davies J, Faulkner G, Pearson J, Langman MJ. Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci 1994;39:706-12.
33. Zimmerman J, Siguencia J, Tsvang E, Beeri R, Arnon R. Predictors of mortality in patients admitted to hospital for acute upper gastrointestinal hemorrhage. Scand J Gastroenterol 1995;30:327-31.
34. United Nations Statistics Division. United Nations Demographic Yearbook-Historical Supplement. New York: United Nations; 1999.
35. Guidry UC, Evans JC, Larson MG, Wilson PW, Murabito JM, Levy D. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham heart study. Circulation 1999;100:2054-9.
36. Nease RF, Kneeland T, O'Connor GT, Sumner W, Lumpkins C, Shaw L, et al. Variation in patient utilities for outcomes of the management of chronic stable angina: implications for clinical practice guidelines: ischemic heart disease patient outcomes research team. JAMA 1995;273:1185-90.
37. Institute of Health Economics. A national list of provincial costs for health care: Canada 1997/8. 1-125. Edmonton, Alberta: Institute of Health Economics; 2000.
38. Alberta Health and Wellness. Health costing in Alberta - 1999 annual report. Edmonton, Alberta: Health and Wellness; 1999.
39. Ontario Ministry of Health. Schedule of benefits: physician services under the health insurance act. Toronto: Ontario Ministry of Health; 1998.
40. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000;139:423-9.
41. Nordmann AJ. Cost-effectiveness of routine echocardiography in hypertensive patients requiring antihypertensive drug therapy. Toronto: University of Toronto; 2001.
42. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000;39:28-33.
43. Sponsor Presentation: FDA Arthritis Advisory Committee. February 7, 2001.
44. Singh G, Goldstein J, Bensen W, Agrawal N, Eisen G, Fort J, et al. SUCCESS-1 in osteoarthritis (OA) trial: celecoxib significantly reduces risk of serious upper GI complications compared to NSAIDs while providing similar efficacy in 13,274 randomized patients [abstract]. European Congress of Rheumatology; Jun 13-16, 2001; Prague. Abstract no OP0053. Available online at URL: http://www.eular.org/eular2001/AbstractsOnline.cfm.